34.5% Below Target

The consensus Wall Street price target for HCA is $504.73, representing 34.5% upside from the current price of $375.17. With 46 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

HCA has a consensus rating of "Buy" based on 46 Wall Street analysts. The rating breakdown is predominantly bullish, with 30 Buy/Strong Buy ratings. The consensus 12-month price target of $504.73 implies 34.5% upside from current levels.

With a forward P/E of 12.4324x, HCA trades at a relatively low valuation. The consensus target of $504.73 implies 34.5% appreciation, suggesting meaningful undervaluation.

The most bullish Wall Street analyst has a price target of $635 for HCA, while the most conservative target is $413. The consensus of $504.73 represents the median expectation. Our quantitative valuation model projects a bull case target of $637 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

HCA is heavily covered by Wall Street, with 46 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 30 have Buy ratings, 14 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month HCA stock forecast based on 46 Wall Street analysts shows a consensus price target of $504.73, with estimates ranging from $413 (bear case) to $635 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $483, with bear/bull scenarios of $304/$637.

Our quantitative valuation model calculates HCA's fair value at $483 (base case), with a bear case of $304 and bull case of $637. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.

HCA trades at a forward P/E ratio of 12.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 13.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Wall Street analysts are very optimistic on HCA, with a "Buy" consensus rating and $504.73 price target (34.5% upside). 30 of 46 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

HCA analyst price targets range from $413 to $635, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $504.73 consensus represents the middle ground. Our model's $304-$637 range provides an independent fundamental perspective.